Reporter Kim focused on EOFlow's newly established pharmaceutical subsidiary 'Pharmeo'.
EOFlow's CEO Jesse Kim expected the drug delivery business as a momentum to exceed global competitors.
Jesse also explained the other subsidiary 'Nephria Bio' which develops wearable artificial kidneys.